Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Ergomed To List On AIM Next Week After Raising GBP11 Million

Wed, 9th Jul 2014 08:53

LONDON (Alliance News) - Pharmaceuticals services and drug development company Ergomed PLC Wednesday said it will list on AIM on July 15 after raising GBP11 million gross in an initial public offering, money it will use to fund the acquisition of its sister company and further deals.

The company priced its IPO at 160 pence, giving it an initial market capitalisation of GBP46.0 million.

Once admitted to trading, it will complete its acquisition of drug safety and medical information services company PrimeVigilance, its sister company, for cash and shares. It is paying GBP6 million in cash and 1.9 million new shares worth GBP3 million at the IPO price.

The UK-based specialist in oncology, neurology, immunology and the development of orphan drugs said it will use the remainder of the GBP9.7 million net proceeds from its IPO to make further acquisitions, buy a proven data management/biostatistics platform to increase the data management capability of its services business, and to expand its rare disease franchise.

"This listing provides a great opportunity to expand and accelerate our growth as we look to become one of the leading global providers for rare disease/orphan drug development services, post marketing services and to expand our portfolio of co-development partnerships," Chief Executive Miroslav Reljanovic said in a statement.

Ergomed and PrimeVigilance combined generated GBP19.2 million in pro forma revenue in 2013.

By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News

Britain free of coronavirus by August, outgoing vaccine task force chief says -Telegraph

May 7 (Reuters) - The new coronavirus will no longer be circulating in Britain by August, the government's departing vaccine taskforce chief Clive Dix told the Daily Telegraph on Friday."Sometime in August, we will have no circulating virus in th...

Today 00:15

UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ

(Adds background related to AstraZeneca vaccine)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application...

7 May 21 23:23

UPDATE 2-AstraZeneca weighs seeking full, not emergency, U.S. approval for COVID-19 shot - WSJ

(Adds response from AstraZeneca in paragraphs 3 and 4)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive appli...

7 May 21 23:23

AstraZeneca weighs seeking full U.S. approval for COVID-19 shot -WSJ

May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, ...

7 May 21 22:52

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.